CortagenvsTestagen

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide belonging to the Khavinson family of peptide bioregulators — short peptides proposed to regulate gene expression in a tissue-specific manner. The bioregulator hypothesis, developed by Professor Vladimir Khavinson over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides (2-4 amino acids) can penetrate cell membranes and nuclear envelopes, interact directly with DNA in a sequence-specific manner, and modulate transcription of tissue-relevant genes.

Cortagen is specifically designed to target neurons of the cerebral cortex. According to the Khavinson model, the AEDP tetrapeptide sequence has complementarity to specific DNA sequences in gene promoter regions active in cortical neurons. Upon binding to these regulatory elements, Cortagen is proposed to modulate chromatin structure and transcription factor access, influencing the expression of genes involved in neuronal function, synaptic transmission, antioxidant defense, and protein synthesis. The tissue specificity — cortex rather than other brain regions or body tissues — is attributed to the unique chromatin accessibility and transcription factor environment in cortical neurons that determines which genes are available for regulation.

Preclinical studies from Russian research programs have reported that Cortagen treatment improves cognitive function, enhances learning and memory, and provides neuroprotection in models of cerebral ischemia and age-related cognitive decline. The proposed mechanism involves restoration of age-related declines in protein synthesis in cortical neurons, enhancement of antioxidant enzyme expression (SOD, catalase, GPx), and improved synaptic function through upregulation of synaptophysin and other synaptic proteins. It should be noted that the peptide bioregulator field remains controversial in Western pharmacology — while the Russian research program is extensive, the proposed direct DNA-binding mechanism has not been independently validated through the standard molecular biology methods expected in Western peer-reviewed literature.

Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.

Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.

As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.